Valsartan
valsartan · Brand: Diovan
Valsartan Indications
| Indication | Approved Population | Therapy Type | Status |
|---|---|---|---|
| Hypertension | Adults & children ≥1 year | Monotherapy or combination | FDA Approved |
| Heart failure (NYHA class II–IV) — reduce hospitalization | Adults | Adjunctive to standard HF therapy (diuretics, digoxin, beta-blockers); no added benefit when combined with adequate-dose ACE inhibitor | FDA Approved |
| Post-myocardial infarction — reduce CV mortality in LV failure or LV dysfunction | Clinically stable adults | Monotherapy (alternative to captopril) or adjunctive to standard post-MI therapy | FDA Approved |
Valsartan is unique among ARBs in holding three distinct FDA-approved cardiovascular indications. Unlike losartan, valsartan is not a prodrug and does not depend on hepatic CYP-mediated activation, making its pharmacological effect more predictable across patients. The Val-HeFT trial (NEJM 2001) demonstrated a 13.2% reduction in the combined mortality-morbidity endpoint (RR 0.87, p=0.009) and a significant reduction in heart failure hospitalisations (13.8% vs 18.2% placebo, p<0.001). The VALIANT trial (NEJM 2003) established valsartan 160 mg twice daily as non-inferior to captopril 50 mg three times daily for reducing CV mortality post-MI, providing an important ACE inhibitor alternative with better tolerability.
Diabetic nephropathy / Chronic kidney disease with proteinuria: ARBs as a class are recommended for renoprotection in T2DM with albuminuria per KDIGO 2024 and ADA 2025 guidelines. Valsartan is used in this context, though losartan and irbesartan have the largest specific nephropathy trial evidence. Evidence quality: High (class effect; MARVAL trial supportive for valsartan specifically).
Heart failure with reduced ejection fraction as ACE inhibitor alternative: Valsartan is specifically positioned by AHA/ACC/HFSA guidelines as an alternative to ACE inhibitors in intolerant patients. The newer combination sacubitril/valsartan (Entresto) has largely superseded standalone valsartan in HFrEF. Evidence quality: High.
Dosing
Adult Dosing by Clinical Scenario
| Clinical Scenario | Starting Dose | Maintenance Dose | Maximum Dose | Notes |
|---|---|---|---|---|
| Hypertension — monotherapy | 80–160 mg once daily | 80–320 mg once daily | 320 mg/day | Antihypertensive effect substantially present within 2 weeks; maximal reduction at 4 weeks Addition of diuretic more effective than dose increases beyond 80 mg |
| Heart failure — NYHA class II–IV | 40 mg twice daily | 80–160 mg twice daily | 320 mg/day (divided BID) | Uptitrate to highest tolerated dose; consider reducing concomitant diuretics Val-HeFT used 160 mg BID target; no added benefit with adequate-dose ACEi |
| Post-MI — LV failure or LV dysfunction | 20 mg twice daily | Target 160 mg twice daily | 320 mg/day (divided BID) | May initiate as early as 12 hours after MI; uptitrate within 7 days to 40 mg BID, then to target VALIANT dose; reduce if hypotension or renal dysfunction occurs |
Paediatric Dosing (Hypertension, ≥1 year)
| Clinical Scenario | Starting Dose | Maintenance Dose | Maximum Dose | Notes |
|---|---|---|---|---|
| Paediatric hypertension (1–16 years) | 1 mg/kg once daily (max 40 mg) | 1–4 mg/kg once daily | 4 mg/kg/day (max 160 mg/day) | Oral suspension (4 mg/mL) available for children unable to swallow tablets Suspension has 60% higher AUC than tablets — do not substitute mg-for-mg; not recommended <1 year |
Valsartan is not a prodrug, so its activity does not depend on hepatic CYP metabolism — a key advantage over losartan in patients with hepatic impairment or CYP2C9 polymorphisms. However, food substantially reduces valsartan exposure (AUC decreased by ~40%, Cmax by ~50%), so consistent timing relative to meals is important. In heart failure and post-MI settings, twice-daily dosing is required for adequate 24-hour AT1 blockade. The oral suspension delivers 60% higher systemic exposure than tablets, requiring dose adjustment when switching formulations. No renal dose adjustment is needed, but valsartan is not removed by haemodialysis.
Pharmacology
Mechanism of Action
Valsartan is a non-peptide, orally active, selective angiotensin II type 1 (AT1) receptor blocker. It blocks the vasoconstrictive and aldosterone-secreting effects of angiotensin II by selectively binding the AT1 receptor in vascular smooth muscle, adrenal gland, and other tissues. Unlike losartan, valsartan is not a prodrug and does not require hepatic conversion to an active metabolite — the parent compound itself is responsible for the pharmacological effect. It does not inhibit ACE (kininase II) and therefore does not cause bradykinin accumulation, resulting in a significantly lower cough incidence than ACE inhibitors. At the 80 mg dose, valsartan inhibits the angiotensin II pressor response by approximately 80% at peak, with about 30% inhibition persisting at 24 hours. Blockade of AT1 receptors removes negative feedback on renin secretion, resulting in elevated plasma renin activity and circulating angiotensin II levels, but these do not overcome the receptor blockade.
ADME Profile
| Parameter | Value | Clinical Implication |
|---|---|---|
| Absorption | Oral bioavailability ~25% (range 10–35%) for tablets; Tmax 2–4 h; food decreases AUC by ~40% and Cmax by ~50%; dose-proportional pharmacokinetics across clinical range | Relatively low bioavailability offset by high receptor affinity; food effect is significant — advise consistent timing relative to meals; suspension has 60% higher AUC than tablets |
| Distribution | Vd 17 L (IV data); protein binding ~95% (albumin); does not distribute extensively into tissues; minimal CNS penetration | Limited tissue distribution; highly protein-bound so not removed by haemodialysis; no dose adjustment needed for renal impairment |
| Metabolism | Not a prodrug; minimal CYP-mediated metabolism; ~20% recovered as metabolites; primary metabolite valeryl 4-hydroxy valsartan (~9% of dose, essentially inactive, ~1/200th AT1 affinity) | Independence from CYP450 system minimises pharmacokinetic drug interactions — major advantage over losartan; no prodrug activation step means predictable effect in hepatic impairment |
| Elimination | t½ ~6 h (oral); ~83% recovered in faeces, ~13% in urine (mainly unchanged); biliary excretion is the major pathway; total clearance ~2 L/h; renal clearance ~0.62 L/h; not removed by haemodialysis | Biliary elimination predominates; hepatic impairment doubles AUC (use with caution); faecal recovery is mainly unchanged drug; no dose adjustment for renal impairment including dialysis |
Side Effects
Valsartan has been evaluated for safety in more than 4,000 hypertensive patients, 5,010 heart failure patients (Val-HeFT), and 14,703 post-MI patients (VALIANT). Adverse reactions have generally been mild and transient. The side effect profile differs meaningfully between the hypertension, heart failure, and post-MI populations due to underlying disease severity and concomitant medications.
| Adverse Effect | Incidence | Clinical Note |
|---|---|---|
| Dizziness | 17% (vs 9% placebo) | Most common adverse effect in HF patients; dose-related; usually manageable with slower titration |
| Adverse Effect | Incidence | Clinical Note |
|---|---|---|
| Dizziness (HTN) | 2–4% (10–160 mg); 8% at 320 mg | Dose-related in hypertension; significantly more common at the highest dose |
| Hypotension (HF) | 7% (vs 2% placebo) | Expected pharmacological effect in HF; assess volume status; rarely requires permanent discontinuation |
| Diarrhoea (HF) | 5% (vs 4% placebo) | Generally self-limiting; evaluate other causes in heart failure patients on multiple medications |
| Viral infection (HTN) | 3% (vs 2% placebo) | Marginally above placebo; not considered drug-related |
| Fatigue (HTN) | 2% (vs 1% placebo) | Check for excessive blood pressure lowering if persistent |
| Abdominal pain (HTN) | 2% (vs 1% placebo) | Mild; evaluate if persistent to rule out hepatic or GI aetiology |
| Arthralgia (HF) | 3% (vs 2% placebo) | Musculoskeletal; monitor if concurrent statin therapy |
| Back pain (HF) | 3% (vs 2% placebo) | Common in HF population; generally not requiring dose change |
| Hyperkalemia (HF) | 2% (vs 1% placebo) | Monitor K+ closely, especially with concomitant ACE inhibitor, K-sparing diuretics, or renal impairment |
| Cough | 2.6% (vs 7.9% ACEi; vs 1.5% placebo) | Significantly lower than ACE inhibitors in comparative trials; in cough-prone patients: 20% valsartan vs 69% lisinopril (p<0.001) |
| Adverse Effect | Estimated Frequency | Typical Onset | Required Action |
|---|---|---|---|
| Angioedema | Rare (postmarketing) | Any time | Discontinue immediately; emergency airway management; never rechallenge; some patients had prior ACEi angioedema |
| Severe hypotension (HTN) | 0.1% | First dose, volume-depleted patients | Place supine; IV normal saline; correct volume depletion before restarting at lower dose |
| Acute renal failure | Uncommon; postmarketing reports | Days to weeks | Discontinue or reduce dose; evaluate for renal artery stenosis; monitor creatinine |
| Creatinine >50% increase (HF) | 3.9% (vs 0.9% placebo) | Weeks to months | Monitor renal function closely in HF; reduce dose or hold if progressive; consider whether RAAS blockade benefit outweighs risk |
| Neutropenia (HF) | 1.9% (vs 0.8% placebo) | Weeks to months | Monitor CBC periodically in HF patients; discontinue if neutrophils <1,000/mm³ |
| Hepatitis (postmarketing) | Very rare | Variable | Discontinue; monitor LFTs; consider alternative antihypertensive class |
| Rhabdomyolysis (postmarketing) | Very rare | Variable | Discontinue; check CK; aggressive hydration; monitor renal function |
| Reason for Discontinuation | Incidence | Context |
|---|---|---|
| Overall adverse events (VALIANT) | 5.8% (vs 7.7% captopril) | Post-MI population; lower overall discontinuation than ACE inhibitor comparator |
| Hypotension (VALIANT) | 1.4% (vs 0.8% captopril) | Post-MI population; pharmacological effect; reduce dose rather than discontinue when possible |
| Cough (VALIANT) | 0.6% (vs 2.5% captopril) | Substantially lower than ACE inhibitor comparator; valsartan advantage for tolerability |
| Creatinine elevation (HF) | 0.5% | Val-HeFT; compared to 0.1% placebo |
| Potassium elevation (HF) | 0.5% | Val-HeFT; compared to 0.1% placebo |
In heart failure trials, BUN increases greater than 50% were observed in 16.6% of valsartan-treated patients compared to 6.3% on placebo, and creatinine increases greater than 50% in 3.9% vs 0.9%. These renal changes are expected pharmacological effects of RAAS blockade in the heart failure population and require close monitoring, particularly during initiation and uptitration.
Drug Interactions
Valsartan has a favourable pharmacokinetic interaction profile because it does not undergo significant CYP450-mediated metabolism. No clinically significant interactions have been identified with hydrochlorothiazide, amlodipine, atenolol, cimetidine, digoxin, furosemide, glyburide, indomethacin, or warfarin in formal interaction studies. The primary interactions are pharmacodynamic, related to potassium homeostasis and renal haemodynamics.
Monitoring
- Blood PressureEach visit; 2–4 weeks after dose changes
RoutineAntihypertensive effect substantially present within 2 weeks; maximal at 4 weeks. In post-MI and HF patients, monitor for symptomatic hypotension during uptitration. Orthostatic assessment recommended at initiation. - Serum PotassiumBaseline, 1–2 weeks after initiation, then periodically
RoutineHyperkalemia occurred in 2% (vs 1% placebo) in HF trials. Higher risk with concomitant K-sparing agents, ACE inhibitors, renal impairment, or diabetes. Hold if K+ >5.5 mEq/L. - Renal FunctionBaseline, 1–2 weeks, then every 3–6 months; more frequently in HF
RoutineCreatinine >50% increases in 3.9% of HF patients (vs 0.9% placebo); BUN >50% increases in 16.6% (vs 6.3%). A rise up to 30% is acceptable if stable. Investigate if >30% or progressive. - Complete Blood CountPeriodically in HF patients
Trigger-basedNeutropenia observed in 1.9% (vs 0.8% placebo) in heart failure trials. Monitor CBC if infection signs develop. - Hepatic FunctionIf signs of hepatic injury develop
Trigger-basedVery rare postmarketing reports of elevated liver enzymes and hepatitis. Discontinue if jaundice or significant transaminase elevation occurs. Hepatic impairment doubles valsartan exposure. - Cardiac FunctionAs per guideline-directed management
Trigger-basedIn HF patients: assess NYHA class, LVEF, and volume status at follow-up visits. In post-MI: reassess LV function at 1–3 months per cardiology guidelines. Consider transition to sacubitril/valsartan if stable HFrEF.
Contraindications & Cautions
Absolute Contraindications
- Hypersensitivity: Known allergy to valsartan or any component of the formulation.
- Pregnancy: Contraindicated at any stage; direct fetal toxicity (FDA Boxed Warning).
- Aliskiren co-administration in diabetes: Contraindicated due to increased renal, hypotensive, and hyperkalaemic risk.
Relative Contraindications (Specialist Input Recommended)
- Bilateral renal artery stenosis or stenosis of a solitary kidney: Risk of acute renal failure; specialist assessment required.
- Severe hepatic impairment or biliary obstruction: Biliary excretion is the primary elimination pathway; valsartan exposure approximately doubled even in mild-to-moderate liver disease. No dosing recommendations for severe hepatic impairment.
- Severe volume depletion: Risk of symptomatic hypotension; correct volume status prior to initiation.
Use with Caution
- Heart failure with triple neurohumoral blockade: Val-HeFT post hoc analysis showed an adverse trend on mortality when valsartan was added to both an ACE inhibitor and a beta-blocker. While this finding was not confirmed in VALIANT, exercise caution with triple RAAS/sympatholytic blockade.
- Renal impairment: No dose adjustment needed, but monitor K+ and creatinine closely. Not recommended in paediatric patients with GFR <30 mL/min/1.73 m².
- Elderly patients: No specific dose adjustment required, but greater sensitivity to blood pressure lowering cannot be excluded.
When pregnancy is detected, discontinue valsartan as soon as possible. Drugs acting directly on the renin-angiotensin system can cause injury and death to the developing fetus, including oligohydramnios, fetal renal failure, hypotension, skull hypoplasia, and neonatal death. Breastfeeding is not recommended during valsartan treatment.
Patient Counselling
Purpose of Therapy
Valsartan works by blocking the effects of a hormone called angiotensin II, which causes blood vessels to constrict and the body to retain salt and water. By blocking this hormone, valsartan helps relax blood vessels, lower blood pressure, and reduce the workload on the heart. Depending on why it has been prescribed, it may be used to control blood pressure, help the heart recover after a heart attack, or reduce the risk of hospital admission for heart failure.
How to Take
Take valsartan as directed by your prescriber. For high blood pressure, it is usually taken once daily. For heart failure or after a heart attack, it is typically taken twice daily. Try to take it at the same time each day. Food reduces how much of the medication your body absorbs, so try to be consistent about whether you take it with or without food. Do not stop taking valsartan without consulting your doctor, even if you feel well.
Sources
- Diovan (valsartan) tablets prescribing information. Novartis Pharmaceuticals Corp. Revised April 2021. FDA Label PDFCurrent FDA-approved prescribing information; primary source for all dosing, contraindications, adverse reactions, drug interactions, and PK data referenced in this monograph.
- Cohn JN, Tognoni G; Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med. 2001;345(23):1667–1675. doi:10.1056/NEJMoa010713Val-HeFT trial (n=5,010); demonstrated 13.2% reduction in combined mortality-morbidity and 27.5% reduction in HF hospitalisations with valsartan added to standard therapy.
- Pfeffer MA, McMurray JJ, Velazquez EJ, et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med. 2003;349(20):1893–1906. doi:10.1056/NEJMoa032292VALIANT trial (n=14,703); established valsartan 160 mg BID as non-inferior to captopril for CV mortality post-MI; combination offered no benefit with more adverse events.
- Maggioni AP, Latini R, Carson PE, et al. Valsartan reduces the incidence of atrial fibrillation in patients with heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT). Am Heart J. 2005;149(3):548–557. doi:10.1016/j.ahj.2004.09.033Val-HeFT substudy showing 37% reduction in atrial fibrillation incidence with valsartan in chronic heart failure patients.
- Viberti G, Wheeldon NM; MicroAlbuminuria Reduction With VALsartan (MARVAL) Study Investigators. Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus. Circulation. 2002;106(6):672–678. doi:10.1161/01.CIR.0000024416.33113.0AMARVAL trial demonstrating valsartan 80 mg reduced microalbuminuria by 44% in T2DM patients, independent of blood pressure changes; supports off-label use for diabetic nephropathy.
- Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure. Circulation. 2022;145(18):e895–e1032. doi:10.1161/CIR.0000000000001063Positions ARBs as alternative to ACEi in HFrEF; recommends transition to sacubitril/valsartan for eligible HFrEF patients; directly relevant to valsartan’s heart failure indication.
- Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults. J Am Coll Cardiol. 2018;71(19):e127–e248. doi:10.1016/j.jacc.2017.11.006US hypertension guideline positioning ARBs as first-line agents for compelling indications including HF, post-MI with LV dysfunction, CKD, and diabetes.
- KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int. 2024;105(4S):S117–S314. doi:10.1016/j.kint.2023.10.018Updated CKD guideline recommending RAAS blockade (ACEi or ARB) for renoprotection in diabetic albuminuria; supports off-label use of valsartan.
- Jugdutt BI. Valsartan in the treatment of heart attack survivors. Vasc Health Risk Manag. 2007;3(5):629–639. PMC1993995Comprehensive review of RAAS inhibition rationale, Val-HeFT and VALIANT mechanistic insights, and clinical evidence for valsartan in post-MI heart failure.
- Benge CD, Muldowney JAS III. The pharmacokinetics and pharmacodynamics of valsartan. Expert Opin Drug Metab Toxicol. 2012;8(11):1469–1482. doi:10.1517/17425255.2012.721776Detailed PK/PD review covering valsartan’s non-prodrug pharmacology, minimal CYP involvement, biliary elimination, and comparison with other ARBs.
- Flesch G, Muller P, Lloyd P. Absolute bioavailability and pharmacokinetics of valsartan, an angiotensin II receptor antagonist, in man. Eur J Clin Pharmacol. 1997;52(2):115–120. doi:10.1007/s002280050259Foundational PK study establishing absolute bioavailability (~23–39%), Vd (17 L), clearance (2.2 L/h), and biphasic elimination kinetics of valsartan.